In this episode, Darrell White, MD, discusses Omidria and how and why it’s used in cataract surgery. He also shares his thoughts on the pass-through status of this product and others and where things are headed.    

• Disclaimer :09
• Introduction :20
• Financial disclosures :50
• What is Omidria, how is it used, and why is it controversial? 1:40
• Along came floppy iris syndrome 2:10
• The difficulty in predicting when IFIS will occur 5:09
• The importance of pupil size in cataract surgery 7:59
• Why people are not using Omidria 10:50
• What makes Omidria controversial 12:50
• Background on the pass-through regulation 13:22
  • How the price is set and how it is paid for 14:13
  • A 3-year deadline and use it or lose it funds 18:10
  • What happens when passthrough ends 20:26
• What happened in December 2017? 24:41
• The pass-through extension 26:30
• Mass confusion over when the 2-year period begins 27:41
• Omeros is not the bad actor here 29:47
• Congress hasn’t done its job 30:33
• A decision needs to be made one way or the other 32:13
• And about mitomycin C 33:56